Updates to the Alberta Human Services Drug Benefit Supplement Effective November 1, 2014 Inquiries should be directed to:

First Page		Document Content
Date: 2014-11-24 17:45:45 Organofluorides Eculizumab Immunosuppressants Merck Ezetimibe Pharmacy Galantamine Dutasteride Methadone Chemistry Organic chemistry Lactams		Updates to the Alberta Human Services Drug Benefit Supplement Effective November 1, 2014 Inquiries should be directed to: Add to Reading List Source URL: www.ab.bluecross.ca Download Document from Source Website File Size: 165,03 KB Share Document on Facebook

	Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris DocID: 1pPKn - View Document
	HUS ParisMode de compatibilité] DocID: 1oXIv - View Document
	1 INTERIM FUNDING CRITERIA IN ONTARIO FOR SOLIRIS AHUS –CASE BY CASE BASIS Initiation Criteria A patient must meet all three of the following to obtain funding for initial treatment of eculizumab for aHUS: 1. Confirmed DocID: 19QJ8 - View Document
	Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands Alexion’s metabolic franchise wi DocID: 19nD4 - View Document
	PDF Document DocID: 16wNC - View Document